Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative propranolol + etodolac for resectable colorectal cancer
ACTRN12612000852853Phase 2Recruiting
- Sponsor
- Khaled Madbouly
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing Placebo with Propranolol + etodolac (2 arms). Primary endpoint: Tumor recurrence. Started Aug 2012; status: recruiting.
02
Drugs
propranololetodolac
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12612000852853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000852853.